SEHA confirms Sotrovimab's success in treating COVID-19 cases

SEHA confirms Sotrovimab's success in treating COVID-19 cases

Abu Dhabi Health Services Company (SEHA) has achieved tremendous success in treating COVID-19 infected patients using the newly-development anti-viral treatment Sotrovimab. Over the past few months, the largest healthcare network in the UAE has boosted the country's response against COVID-19 with the provision of effective and efficient medical treatments.

Dr. Anwar Salam, SEHA Chief Medical Officer, thanked the Department of Health – Abu Dhabi for its rapid response in approving the emergency use of Sotrovimab as it generated positive results in treating patients infected with COVID-19 in a short timeframe.

"As the cornerstone of the UAE’s healthcare landscape and the frontrunners in the nation’s response to the pandemic, we are empowered to bring pioneering services and treatment methods to our community," Dr Salam said.

36-year-old Saeed Al Ameri was quarantining at his residence after testing positive for COVID-19 earlier this time. However, he started experiencing high fever, headaches, and body pain due to COVID-19, following which he was admitted to the intensive care unit at Sheikh Khalifa Medical City (SKMC) under the SEHA network. In the medical centre, he was prescribed Sotrovimab and soon after the treatment began, Saeed’s fever began to drop and his overall health condition showcased remarkable improvement. He was discharged within four days of treatment. Al Ameri’s wife and mother also experienced extreme repercussions after contracting COVID-19 and their health began to deteriorate. As soon as they were transferred to SKMC’s intensive care unit, they were also prescribed Sotrovimab treatment which helped both of them in rapid recovering and getting discharged from the hospital within four days.

Narrating his experience, Saeed Al Ameri expressed gratitude to UAE leaders for their remarkable response to the pandemic.

"May the UAE be blessed with health, wellness, security, and safety. The unprecedented healthcare me and my family received from the SKMC team was life-saving, I am forever thankful to the entire team," he added.

Another patient, Allawi Saleh Ali Al Mansouri, also shared his journey to recovery from COVID-19 at SKMC, underlining that Sotrovimab has significant contribution in his recovery from the virus.

"Shortly after receiving the medication, my condition drastically improved, and I was discharged completely healthy. I thank the medical team for their efforts and outstanding healthcare," Al Mansouri said.

May Siddiq Mansour thanked the UAE for providing the effective treatment to help COVID-19 in recovering from the disease.

"I pray for the nation’s leaders and healthcare providers to be blessed abundantly for all their hard work in the fight against the pandemic," he added.

The US Food & Drug Administration (FDA) and UAE Ministry of Health & Prevention (MOHAP) approved Sotrovimab for treating COVID-19 illness under an Emergency Use Authorization (EUA). Sotrovimab is developed by GSK - science-led global healthcare company with expertise in high quality medicines, vaccines and consumer healthcare products. The early-stage treatment has helped in significant reduction in the number of cases requiring hospitalization for over 24 hours and minimizing COVID-19 death by at least 85% in the UAE. 


Share the article: